StreetInsider.com News Articles

Oppenheimer Reiterates Perform Rating on Procept BioRobotics Corp (PRCT)

Wed, 09 Sep 2026 06:17:44 -0400

Oppenheimer analyst Suraj Kalia reiterated a Perform rating on Procept BioRobotics Corp (NASDAQ: PRCT).

The analyst comments "The Aquablation procedure vs. handpiece inventory dynamic currently dominates the PRCT debate. Blurred out in this debate is the call option of the WATER-IV pivotal trial evaluating Aquablation vs. radical prostatectomy in prostate cancer (PCa). This 280-patient 1:1 RCT designed for superiority of Aquablation is expected to have topline readout at AUA 2027. Our field checks have been picking up significantly longer Aquablation procedure times in PCa vs. BPH, hence we did some deep field checks to understand if so, why so. Our findings

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SM

Tue, 08 Sep 2026 10:17:33 -0400

PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); Hyliion Holdings Corp. (NYSE: HYLN); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Off

Thu, 03 Sep 2026 08:47:51 -0400

PHILADELPHIA, Sept. 03, 2026 (GLOBE NEWSWIRE) --

ERASCA, INC. (NASDAQ: ERAS):

Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.

What is This Investigation About? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.

If you are a current

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Wed, 02 Sep 2026 21:47:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - September 2, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and Approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Wed, 02 Sep 2026 21:47:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - September 2, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Mon, 31 Aug 2026 13:29:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Mon, 31 Aug 2026 13:29:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Fri, 28 Aug 2026 18:06:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 28, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Fri, 28 Aug 2026 18:06:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 28, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Wed, 26 Aug 2026 22:12:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 26, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern

PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,

Wed, 26 Aug 2026 22:12:00 -0400

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 26, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern